Pertuzumab Injection

Pertuzumab is used to treat breast cancer.
Pertuzumab is contraindicated in patients with known hypersensitivity to pertuzumab or any of its excipients.
The patient’s cardiac function needs to be evaluated before and during treatment. If clinically significant left ventricular function is confirmed… Details 
Pertuzumab comprehensive interpretation

Effects:
This product is used to treat breast cancer.
Dosage and administration:
Recommended dose/dosing regimen for metastatic breast cancer and early breast cancer: The recommended starting dose of this product is 840 mg, intravenous infusion over 60 minutes, and then once every 3 weeks, the dose is 420 mg, and the infusion time is 30-60 minutes. After each pertuzumab infusion, it is recommended to observe for 30-60 minutes. After the observation, trastuzumab or chemotherapy can be continued. Pertuzumab and trastuzumab must be administered sequentially, but the two can be administered in any order. When trastuzumab is used in combination with pertuzumab, a 3-week course of treatment is recommended, with a starting dose of 8 mg/kg of trastuzumab administered intravenously over 90 minutes, followed by 6 mg/kg of trastuzumab administered intravenously over 30 to 90 minutes every 3 weeks thereafter. For patients receiving taxanes, pertuzumab and trastuzumab should be administered prior to the taxane. The recommended starting dose of docetaxel when used in combination with pertuzumab is 75 mg/m2, which can be escalated to 100 mg/m2 depending on the regimen chosen and tolerance to the starting dose. If combined with a carboplatin-based chemotherapy regimen, the dose of docetaxel should always be 75 mg/m2 (no dose escalation). When adjuvant therapy is paclitaxel combined with pertuzumab, paclitaxel is recommended at 80 mg/m2 weekly for a total of 12 weeks. For patients receiving anthracycline therapy, pertuzumab and trastuzumab should be given after completing a complete anthracycline regimen. Metastatic breast cancer: Pertuzumab is used in combination with trastuzumab and docetaxel until disease progression or intolerable toxicity occurs. Even if docetaxel treatment is terminated, treatment with pertuzumab and trastuzumab can continue. Early breast cancer: When used for preoperative neoadjuvant treatment, patients are recommended to receive 3 to 6 cycles of pertuzumab treatment, depending on the regimen selected for the combination of trastuzumab and chemotherapy. When used for postoperative adjuvant treatment, this product should be combined with trastuzumab every 3 weeks for 1 year (up to 18 cycles) or until disease recurrence or intolerable toxicity occurs (whichever occurs first), and constitutes a complete treatment regimen for early breast cancer with standard chemotherapy containing anthracyclines and/or taxanes. This product combined with trastuzumab should be started on the first day of the first cycle of taxane-containing treatment. Even if chemotherapy is discontinued, trastuzumab and pertuzumab treatment should be continued for 1 year. Patients who start pertuzumab and trastuzumab treatment during neoadjuvant therapy should continue to receive pertuzumab and trastuzumab during adjuvant therapy to complete 1 year of treatment. The same drug produced by different manufacturers may have inconsistent instructions. If you find inconsistencies in the drug instructions before taking the drug, please consult a doctor or pharmacist in time.
Drug contraindications:
Contraindicated if allergic to this product
Related dosage forms:
Injection